Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer

Clinical Infectious Diseases

Volumn 52, Issue 1, 2011, Pages 86-88

  Watts, Matthew R ^a   Taylor, Peter C ^b   Sintchenko, Vitali ^c   Whelan, Clair M ^e   Farnsworth, Robert H ^d   Jones, Philip ^d   Jelfs, Peter ^a   Carr, David ^b   Goldberg, Hazel ^d  

^a Western Sydney Area Health Service   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLADDER CANCER; BOVINE TUBERCULOSIS; CANCER IMMUNOTHERAPY; CASE REPORT; DYSURIA; FEVER; HEMATURIA; HUMAN; MALE; MULTIPLE ORGAN FAILURE; MYCOBACTERIUM BOVIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEPSIS; AGED; BACTEREMIA; BIOLOGICAL THERAPY; BLADDER TUMOR; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; METHODOLOGY; MICROBIOLOGY;

ADMINISTRATION, INTRAVESICAL; AGED; ANTITUBERCULAR AGENTS; BACTEREMIA; BIOLOGICAL THERAPY; DRUG RESISTANCE, BACTERIAL; HUMANS; IMMUNOTHERAPY; ISONIAZID; MALE; MYCOBACTERIUM BOVIS; URINARY BLADDER NEOPLASMS;

EID: 79951591184     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciq002     Document Type: Article

References (12)

1. Brandau S, Suttmann H. Thirty years of BCG immunotherapy for nonmuscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007;61:299-305. (Pubitemid 47189735)
2. Gonzalez OY, Musher DM, Brar I, et al. Spectrum of Bacille Calmette-Guérin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 2003;36:140-148. (Pubitemid 36143410)
3. Lamm DL, van der Meijin ADPM, Morales A, et al. Incidence and treatment of complications of Bacille Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
4. Rischmann P, Desgarandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side effects management. Eur Urol 2000;37(Suppl 1): 33):33-36. (Pubitemid 30076963)
5. Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N. Susceptibility of Mycobacterium bovis BCG vaccinestrains to antituberculous antibiotics. Antimicrob Agents Chemother 2009;53:316-318.
6. Knezevic I, Corbel MJ. Meeting report: WHO discussion on the improvement of the quality control of BCG vaccines. Vaccine 2006;24:3874-3877.
7. Hesseling AC, Schaaf HS, Victor T, et al. Resistant Mycobacterium bovis Bacillus Calmette-Guérin disease: implications for management of Bacillus Calmette-Guérin disease in human immunodeficiency deficiency virus-infected children. Pediatr Infect Dis J 2004;23:476-479. (Pubitemid 38621494)
8. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centres for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
9. Vicheze C, Jacobs WR Jr. The mechanisms of insoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol 2007;167:603-662.
10. Blumberg HM, Leonard MK Jr., Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005;293:2776-2784. (Pubitemid 40973380)
11. World Health Organization (WHO). Guidelines for the management of drug resistant tuberculosis. Geneva, Switzerland: WHO; 1997. WHO/TB/96.210.
12. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007;51:2329-2336. (Pubitemid 47047307)